Physician profile
Staci Hooker
NPI 1427462746
$4,216.69
in general payments reported to CMS, 2019-2025
25 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $946 · 2022: $1,284 · 2023: $896 · 2024: $855 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,926 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,926.03 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $936.03 | 2021-2024 | Xifaxan, Plenvu, Trulance |
| Abbvie INC. | $882.18 | 2021-2025 | |
| Janssen Biotech, INC. | $738.24 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $303.57 | 2021-2024 | Entyvio |
| Pfizer INC. | $170.04 | 2022-2024 | |
| Ardelyx, INC. | $163.84 | 2022-2024 | Ibsrela |
| Celgene Corporation | $140.44 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $125.22 | 2021-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $120.25 | 2022-2024 | Dupixent |
| Gilead Sciences, INC. | $113.38 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $78.40 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $71.78 | 2022-2024 | Rebyota, Clenpiq |
| Nestle Healthcare Nutrition INC. | $69.70 | 2022 | |
| Merck Sharp & Dohme LLC | $44.59 | 2021-2024 | Dificid |
| Braintree Laboratories, INC. | $37.41 | 2024-2025 | Suflave, Sutab |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $37.38 | 2025 | Myrisk |
| Lilly USA, LLC | $32.45 | 2024 | Omvoh |
| Pharming Healthcare, INC. | $24.24 | 2023 | Ruconest |
| Novo Nordisk INC | $22.51 | 2025 | Wegovy |
| Exact Sciences Corporation | $22.29 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $19.60 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.45 | 2025 | Iqirvo |
| Qol Medical, LLC | $18.21 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.58 | 2023 | Cyltezo |
| Organon LLC | $11.91 | 2023 | Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Hooker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.